Feb 18, 2021 / 03:30PM GMT
Mark Anthony Massaro - BTIG, LLC, Research Division - MD & Life Science & Diagnostic Tools Analyst
All right. Good morning, everyone. Thank you very much for joining the BTIG MedTech, Diagnostics, Digital Health and Tools Conference. I'm joined with Jeff Elliott, the company's Chief Financial Officer of Exact Sciences, and I have a virtual snowbird in my back. And so hopefully, next year, we can all get on the slopes. Jeff, thanks so much for joining.
Jeffrey T. Elliott - Exact Sciences Corporation - CFO
Good morning, Mark. Thanks for having us.
Questions and Answers:
Mark Anthony Massaro - BTIG, LLC, Research Division - MD & Life Science & Diagnostic Tools AnalystTerrific. So you guys recently had your earnings call, a really solid Q4, beating my and Street expectations. Cologuard screening revenue came in at $250 million. That was up 16% sequentially, 9% year-over-year even despite COVID. I guess can you just walk us through what the key drivers of growth were in Q4? And I'm curious if you
Trustpilot
